JP2024509265A - 赤血球増加症を処置するための組成物および方法 - Google Patents

赤血球増加症を処置するための組成物および方法 Download PDF

Info

Publication number
JP2024509265A
JP2024509265A JP2023555275A JP2023555275A JP2024509265A JP 2024509265 A JP2024509265 A JP 2024509265A JP 2023555275 A JP2023555275 A JP 2023555275A JP 2023555275 A JP2023555275 A JP 2023555275A JP 2024509265 A JP2024509265 A JP 2024509265A
Authority
JP
Japan
Prior art keywords
subject
polycythemia
alkyl
group
glyt1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509265A5 (https=
Inventor
ジョン クイセル，
ウィリアム ジェイコブ サベージ，
マリア ガブリエラ ベコーニ，
ヴ ホン，
ミン ウー，
イー シャン，
パヴァン レディ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disc Medicine Inc
Original Assignee
Disc Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disc Medicine Inc filed Critical Disc Medicine Inc
Publication of JP2024509265A publication Critical patent/JP2024509265A/ja
Publication of JP2024509265A5 publication Critical patent/JP2024509265A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023555275A 2021-03-12 2022-03-11 赤血球増加症を処置するための組成物および方法 Pending JP2024509265A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163160412P 2021-03-12 2021-03-12
US63/160,412 2021-03-12
US202163185464P 2021-05-07 2021-05-07
US63/185,464 2021-05-07
PCT/US2022/020038 WO2022192730A1 (en) 2021-03-12 2022-03-11 Compositions and methods for treating polycythemia

Publications (2)

Publication Number Publication Date
JP2024509265A true JP2024509265A (ja) 2024-02-29
JP2024509265A5 JP2024509265A5 (https=) 2025-03-11

Family

ID=83228388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555275A Pending JP2024509265A (ja) 2021-03-12 2022-03-11 赤血球増加症を処置するための組成物および方法

Country Status (10)

Country Link
US (3) US20260027107A1 (https=)
EP (1) EP4304596A4 (https=)
JP (1) JP2024509265A (https=)
KR (1) KR20230169981A (https=)
AU (1) AU2022233178A1 (https=)
BR (1) BR112023018403A2 (https=)
CA (1) CA3213395A1 (https=)
IL (1) IL305806A (https=)
MX (1) MX2023010449A (https=)
WO (1) WO2022192730A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230169981A (ko) * 2021-03-12 2023-12-18 디스크 메디슨, 인크. 적혈구증가증을 치료하기 위한 조성물 및 방법
CN116942668A (zh) * 2023-03-17 2023-10-27 天津医科大学 Glyt1抑制剂在治疗器官纤维化中的应用
AU2024339974A1 (en) * 2023-09-15 2026-03-26 Disc Medicine, Inc. Glyt-1 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180036A1 (ar) * 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
KR20230169981A (ko) * 2021-03-12 2023-12-18 디스크 메디슨, 인크. 적혈구증가증을 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
US20240269132A1 (en) 2024-08-15
US20260027107A1 (en) 2026-01-29
US20250248995A1 (en) 2025-08-07
MX2023010449A (es) 2023-11-09
WO2022192730A1 (en) 2022-09-15
KR20230169981A (ko) 2023-12-18
EP4304596A1 (en) 2024-01-17
CA3213395A1 (en) 2022-09-15
IL305806A (en) 2023-11-01
AU2022233178A1 (en) 2023-10-26
EP4304596A4 (en) 2025-02-19
BR112023018403A2 (pt) 2023-10-10

Similar Documents

Publication Publication Date Title
JP7699592B2 (ja) グリシン輸送阻害剤を用いて骨髄性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球生成性ポルフィリン症を処置する方法
JP2024509265A (ja) 赤血球増加症を処置するための組成物および方法
JP2024509267A (ja) リボソーム障害に関連する貧血を処置するための組成物および方法
RU2646475C2 (ru) Лечение диабета I и II типа
CN118319913A (zh) 用于治疗红细胞增多症的组合物和方法
HK40105387A (zh) 用於治疗红细胞增多症的组合物和方法
US20250228827A1 (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
US20250302823A1 (en) Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors
HK40082113A (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
HK40105830A (zh) 用於治疗与核糖体障碍相关的贫血的组合物和方法
HK40094968B (zh) 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
HK40123243A (zh) 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法
CN117440811A (zh) 用于治疗与核糖体障碍相关的贫血的组合物和方法
HK40094968A (zh) 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250303